— Addition of Soliton complements Body Contouring Portfolio with expansion to treat appearance of cellulite —
Allergan Aesthetics, an AbbVie company announced the successful completion of its acquisition of Soliton, Inc. The addition of Soliton and its technology complements Allergan Aesthetics’ portfolio of non-invasive body contouring treatments to now include a proven treatment for the appearance of cellulite.
The RESONIC™ device initially received U.S. Food and Drug Administration (FDA) 510(k) c******** for the short-term improvement in the appearance of cellulite, and that c******** has now been expanded to long-term improvement up to one year. In recent clinical data submitted to the FDA, RESONIC™ demonstrated significant improvement in the appearance of cellulite and 97.6% of participants (n=67) found there was good improvement in the appearance of cellulite at 52-weeks post-treatment.
Top iTechnology Cloud News: Firebolt Announces Series C Round at $1.4 billion Valuation to Build the World’s Fastest
“We welcome the Soliton team to Allergan Aesthetics and the opportunity to offer health care providers and their patients a new, non-invasive option to reduce the appearance of cellulite,” said Carrie Strom, President, Global Allergan Aesthetics and Senior Vice President, AbbVie. “In a recent survey of aesthetics consumers, cellulite was cited as a top 5 aesthetic concern, and this technology offers a new approach to treatment.”
Top iTechnology Networking News: Panther Protocol Announces Listing on Huobi Creating Privacy Layer for DeFi and Web3
[To share your insights with us, please write to sghosh@martechseries.com]
